Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

(2014) A. Kashiwagi et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

(2014) A. Liakos et al.   DIABETES OBESITY & METABOLISM

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

(2014) S. Sha et al.   DIABETES OBESITY & METABOLISM

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

(2014) Agata Ptaszynska et al.   DRUG SAFETY

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

(2014) Masanori Yokono et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors

(2014) Raymond V. Oliva et al.   Journal of the American Society of Hypertension

Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results

(2014) Keith Usiskin et al.   POSTGRADUATE MEDICINE

Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) Lindsay E. Nicolle et al.   POSTGRADUATE MEDICINE

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

(2014) Alan Sinclair et al.   BMC Endocrine Disorders

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials

(2014) Yu-nan Sun et al.   BMJ Open

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

(2013) Mei Zhang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

(2013) Kristina M. Johnsson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

(2013) Atsunori Kashiwagi et al.   Journal of Diabetes Investigation

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study

(2012) L.E. Nicolle et al.   CURRENT MEDICAL RESEARCH AND OPINION

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

(2012) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study

(2012) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values

(2012) Atsunori Kashiwagi et al.   Journal of Diabetes Investigation